POTENTIAL THERAPEUTIC APPROACHES TO THE TREATMENT OR PREVENTION OF DIABETIC NEUROPATHY - EVIDENCE FROM EXPERIMENTAL STUDIES

被引:100
作者
CAMERON, NE
COTTER, MA
机构
[1] Department of Biomedical Sciences, University of Aberdeen
关键词
DIABETES-MELLITUS; NEUROPATHY; NERVE BLOOD FLOW; VASODILATOR TREATMENT; POLYOL PATHWAY; OXIDATIVE STRESS; ADVANCED GLYCATION; TROPHIC FACTORS;
D O I
10.1111/j.1464-5491.1993.tb00131.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent investigations using experimental models of diabetes mellitus have emphasized the importance of impaired blood flow for the development of nerve dysfunction. Other observations suggest that this may also be the case for patients. A number of studies have revealed that several types of vasodilators can prevent or successfully treat early conduction abnormalities in diabetic rodents. These include alpha1-adrenoreceptor antagonists, calcium channel blockers, agents that inhibit the renin-angiotensin system, and vasomodulator prostanoids. Other treatments applied to animal models, such as omega-6 essential fatty acids, aldose reductase inhibitors, aminoguanidine which prevents the formation of advanced glycation end-products, and anti-oxidants all appear to have vascular-related effects that lead to improvements in nerve conduction. These findings suggest that endothelial dysfunction and oxidative stress could be important factors in the aetiology of diabetic neuropathy. Studies have also focused on deficits in axon growth and regeneration, their relation to impaired neuronal synthesis and transport of growth-related chemicals, and neuronotrophic abnormalities. Taken together, the data give rise to the notion that an optimal therapeutic strategy could consist of improving the microenvironment of damaged nerve fibres by manipulating nerve blood flow while concurrently encouraging repair with trophic agents.
引用
收藏
页码:593 / 605
页数:13
相关论文
共 162 条
  • [41] Kihara M., Low PA., Regulation of rat nerve blood flow: role of epineurial α‐receptors, J Physiol, 422, pp. 145-152, (1990)
  • [42] Tomlinson KC, Gardiner SM, Hebden RA, Bennett T., Functional consequences of streptozotocin‐induced diabetes mellitus, with particular reference to the cardiovascular system, Pharmacol Rev, 44, pp. 103-150, (1992)
  • [43] Morff RJ., Microvascular reactivity to norepinephrine at different arteriolar levels and durations of streptozotocin‐induced diabetes, Diabetes, 39, pp. 354-360, (1990)
  • [44] Zochodne DW, Ward KK, Low PA., Guanethidine adrenergic neuropathy: an animal model of selective autonomic neuropathy, Brain Res, 461, pp. 10-16, (1988)
  • [45] Zochodne DW, Huang Z., Ward KK, Low PA., Guanethidine adrenergic sympathectomy augments endoneurial perfusion and lowers endoneurial microvascular resistance, Brain Res, 519, pp. 112-117, (1990)
  • [46] White RP, Carrier GO., Vascular contraction induced by activation of membrane calcium ion channels is enhanced in streptozotocin‐diabetes, J Pharmacol Exp Ther, 253, pp. 1057-1062, (1990)
  • [47] Macleod KM, McNeill JH., The influence of chronic experimental diabetes on contractile responses of rat isolated blood vessels, Can J Physiol Pharmacol, 63, pp. 52-57, (1984)
  • [48] White RP, Carrier GO., Enhanced vascular α‐adrenergic neuroeffector system in diabetes: importance of calcium, Am J Physiol, 255, (1988)
  • [49] Cameron NE, Cotter MA., Impaired contraction and relaxation in aorta from streptozotocin‐diabetic rats: role of the polyol pathway, Diabetologia, 35, pp. 1011-1019, (1992)
  • [50] Kamata K., Miyata N., Kasuya Y., Functional changes in potassium channels in aortas from rats with streptozotocin‐induced diabetes, Eur J Pharmacol, 166, pp. 319-323, (1989)